Please click on product name to see the Full Prescribing Information for ABILIFY®, ATRIPLA®, AVAPRO®/AVALIDE®, BARACLUDE®, ERBITUX®, IXEMPRA®, ONGLYZA™, ORENCIA®, PLAVIX®, REYATAZ®, SPRYCEL®, SUSTIVA®, including boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, ERBITUX®, IXEMPRA™, and TAXOL®, and boxed WARNINGS for AVAPRO® and AVALIDE® regarding use in pregnancy. As soon as pregnancy is detected, discontinue use of AVAPRO® or AVALIDE®.

Full Development compounds are investigational drugs that are in late-stage clinical development, or have been submitted to regulatory agencies for approval.

Marketed Product Development compounds have been approved in at least one major market and are among approved medicines that are driving current and future growth while continuing their clinical development to determine whether additional indications and formulations will benefit patients. Current medicines in marketed product development include treatments in the areas of cardiovascular disease, HIV/AIDS, psychiatric disorders, rheumatoid arthritis, cancer and virology.

Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.